<DOC>
	<DOCNO>NCT02339532</DOCNO>
	<brief_summary>The main objective multicenter study therefore evaluate pathologic complete response rate anthracycline-based regimen [ FEC 100 - TAXOTERE® - HERCEPTIN® - PERTUZUMAB ] non anthracycline-based regimen [ TAXOTERE® - CARBOPLATINE - HERCEPTIN® - PERTUZUMAB ] accord presence TOP2A gene amplification population breast cancer patient HER2 overexpression . A important objective study evaluation biomarkers predict response treatment .</brief_summary>
	<brief_title>Neoadjuvant Phase II Trial Patients With T1c Operable , HER2-positive Breast Cancer According TOP2A Status</brief_title>
	<detailed_description>In phase II study , propose treatment strategy take advantage complementary action trastuzumab pertuzumab also relevance anthracycline-based regimen . Indeed , besides cardiac toxicity induce three agent , anthracycline chemotherapy may confer benefit patient . The underlie scientific hypothesis base data NEOSPHERE neoadjuvant trial show addition pertuzumab trastuzumab plus docetaxel improved pCR rate ( 46 % versus 29 % without pertuzumab ) T2-T3 tumor . Therefore , hypothesize small tumor ( T1c ) , pCR rate high , order 60 % patient coamplification ( anthracycline therapy ) 55 % group without coamplification ( without anthracycline therapy ) . The sample size 90 patient ( 45 per group ) plan phase II study allow 15 % precision expect pCR rate 60 % ( 95 % CI : 45 % -75 % ) patient coamplification 55 % ( 95 % CI : 40 % -70 % ) without coamplification . In addition , exploratory analysis aim identify predictive marker pCR order target biologically defined subpopulation pCR rate might even high .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women age ≥ 18 ; Patient histologically confirm breast cancer , clinical tumour diameter &gt; 1 cm ≤ 2 cm ( T1c ) ; Clinical stage I IIa ; No clinically radiologically detectable metastasis ( M0 ) ; HR negative ( ER PR &lt; 10 % IHC ) ; Her2 positive ( i.e . IHC score 3+ FISH/SISH/CISH positive ) ; Performance status ≤ 1 ( accord WHO criterion ) ; Patients previously treat surgery , radiotherapy , hormone therapy chemotherapy ; Hæmatology : Absolute neutrophil count ( ANC ) ≥1,500/mm3 ; Platelets ≥100,000/mm3 ; Total white blood cell count ( WBC ) ≥3.000/mm3 ; Hb &gt; 9g/dl ; Hepatic Function : Total bilirubin ≤1.5 time upper normal limit ( UNL ) ; ASAT ≤ 1.5xUNL ; ALAT ≤ 1.5xUNL ; Alkaline phosphatase ≤ 2.5xUNL ; Renal Function : Serum creatinine ≤1.5xUNL ( Serum creatinine &gt; 1.5xUNL , Creatinine clearance ≥50 mL/min ( MDRD formula ) ; Metabolic Function : Magnesium ≥ low limit normal ; Calcium ≥ low limit normal ; Patient control heart disease anthracyclines contraindicate . Cardiac ejection fraction ≥50 % measure MUGA ECHO do within 4 week inclusion ; Patient agree use effective contraception ≥ 7 month completion study treatment ; Patient able comply protocol ; Patient must sign write informed consent form prior study specific procedure ; Patient must affiliate Social Health Insurance . Bilateral multifocal breast cancer ; Nonmeasurable tumour ; Any form breast cancer describe inclusion criterion , particularly inflammatory and/or overlook form ( T4b T4d ) ; HER2 negative status ( i.e . IHC score 0 1+ , IHC score 2+ FISH/SISH/CISH negative ) ; RH positive ( ER PR ≥ 10 % IHC ) ; Patient history second cancer , exception situ cervical cancer basocellular skin cancer regard cure ; Patient already treat new breast cancer ; Patients already undergone surgery disease primary axillary dissection ; Prior docetaxel administration antiHER2 antibody therapy ( e.g . : trastuzumab pertuzumab ) ; Patients concurrent severe and/or uncontrolled medical disease could compromise participation study , , limit : Heart kidney failure , medullary , respiratory liver failure , dyspnea Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia , poorly control hypertension ) ≤ 1 year enrollment Uncontrolled diabetes Significant neurological psychiatric abnormality Symptomatic progressive disorder central nervous system ( CNS ) metastasis initial checkup . Peripheral neuropathy &gt; grade 2 Acute urinary infection , ongoing hemorrhagic cystitis ; Patients know history HIV seropositivity ; Sensitivity study medication ingredient excipients medication ; Patients receive concomitant medication phenytoin ; Patients receive investigational drug within 30 day initiation treatment and/or study ; Must major surgical procedure within 30 day initiation treatment ; Pregnant woman , woman likely become pregnant breastfeeding ; Patients psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial ; Patients history non compliance medical regimen unwilling unable comply protocol ; Individual deprive liberty place authority tutor .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HER2-positive</keyword>
	<keyword>non-metastatic</keyword>
	<keyword>TOP2A</keyword>
</DOC>